Stereoselective and substrate-dependent inhibition of hepatic mitochondrial beta-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen, and ketorolac
Gs. Browne et al., Stereoselective and substrate-dependent inhibition of hepatic mitochondrial beta-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen, and ketorolac, BIOCH PHARM, 57(7), 1999, pp. 837-844
Non-steroidal anti-inflammatory drugs (NSAIDs) cause a range of adverse eff
ects, some of which have been associated with perturbances of lipid metabol
ic pathways. Previous data demonstrating stereoselective formation of the C
oA thioester of R-ibuprofen in particular were suggestive of possible stere
oselective effects on lipid metabolism Our aim was to characterise the rela
tive stereoselectivity of the effects of ibuprofen, flurbiprofen, and ketor
olac (0.01-1.0 mM) on both the beta-oxidation of palmitate and oxidative ph
osphorylation in rat hepatic mitochondria as a means of dissecting prostagl
andin related from non-prostaglandin-related events. beta-oxidation was inh
ibited stereoselectively by R-ibuprofen (P = 0.015), non-stereoselectively
by Rand S-flurbiprofen (P = 0.002 and P = 0.004, respectively), and was ess
entially unaffected by either enantiomer of ketorolac. At 0.25 mM, inhibiti
on by R-ibuprofen and both flurbiprofen enantiomers was partially reversed
by increasing CoA concentrations (0-200 mu M). Mitochondrial respiration wa
s moderately inhibited by both enantiomers of ibuprofen and flurbiprofen (P
< 0.01), but only by high concentrations (greater than or equal to 1 mM) o
f the enantiomers of ketorolac (P < 0.01). Uncoupling of oxidative phosphor
ylation measured as stimulation of State 4 respiration contributed to these
effects. The data support interactions involving both stereoselective CoA-
dependent and non-CoA-dependent mechanisms. The plasma- drug concentrations
required to achieve these effects are not likely to be attained in the maj
ority of patients, although these concentrations are achievable in the gast
rointestinal tract and may contribute to the well-known spectrum of adverse
effects in this organ. Some patients do experience systemic adverse events
which may be mediated by these mechanisms. (C) 1999 Elsevier Science Inc.